The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Trial Profile

The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2008

At a glance

  • Drugs NB 001 (Primary)
  • Indications Herpes labialis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NanoBio Corporation
  • Most Recent Events

    • 28 Oct 2008 Data presented at the annual ICAAC/IDSA meeting in Washington, D.C, USA.
    • 17 Mar 2008 Primary endpoint met; results reported in a NanoBio Corporation media release.
    • 17 Mar 2008 Status change from in progress to completed, based on a NanoBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top